Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

41.76
-0.4100-0.97%
Post-market: 41.760.00000.00%16:10 EDT
Volume:1.27M
Turnover:52.83M
Market Cap:6.65B
PE:-13.93
High:42.57
Open:42.15
Low:41.25
Close:42.17
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Janover, AMC Entertainment, U.S. Steel

Reuters
·
07 Apr

BUZZ-H.C. Wainwright initiates coverage for Ionis  Pharma with 'buy' rating citing pending drug launches

Reuters
·
07 Apr

HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target

MT Newswires Live
·
07 Apr

Ionis Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
07 Apr

Ionis Pharmaceuticals, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $45

THOMSON REUTERS
·
07 Apr

Ionis Pharmaceuticals management to meet with Oppenheimer

TIPRANKS
·
05 Apr

Ionis to host expert panel discussion on sHTG

Business Wire
·
03 Apr

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Dow Jones
·
02 Apr

Ionis Pharmaceuticals Initiated at Neutral by Redburn Atlantic

Dow Jones
·
31 Mar

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target

MT Newswires Live
·
31 Mar

Ionis to present at upcoming investor conferences

Business Wire
·
31 Mar

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Zacks
·
28 Mar

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

Zacks
·
27 Mar

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

MT Newswires Live
·
26 Mar

BRIEF-Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S.

Reuters
·
26 Mar

Ionis Expands Partnership With Sobi to Include Olezarsen Commercialization Outside the U.S.

THOMSON REUTERS
·
26 Mar

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Business Wire
·
26 Mar

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
24 Mar

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Simply Wall St.
·
24 Mar